Curative one-shot systemic virotherapy in murine myeloma.
about
Oncolytic Viruses: Therapeutics With an Identity CrisisFrom scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancerViruses for tumor therapyVesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancerThe use of the NIS reporter gene for optimizing oncolytic virotherapySafety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.The innovative evolution of cancer gene and cellular therapies.Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters.Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy.Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites.Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic VirusesMyxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myelomaHSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapyCharacteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands.Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV.Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo.Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.Oncolytic virotherapyOncolytic vaccines.Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model.Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model.Vesiculovirus neutralization by natural IgM and complement.Oncolytic Virotherapy: A Contest between Apples and Oranges.PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice.Comparative oncology evaluation of intravenous recombinant oncolytic Vesicular Stomatitis Virus therapy in spontaneous canine cancer.Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.Designing and building oncolytic viruses.Potential of oncolytic viruses in the treatment of multiple myeloma.Oncolytic Viruses for Multiple Myeloma Therapy.Combination of IAP Antagonists and TNF-α-Armed Oncolytic Viruses Induce Tumor Vascular Shutdown and Tumor Regression
P2860
Q26741020-85A894C7-9645-4D0E-AC99-698E287625ABQ26822694-4B29A359-2D3F-4C62-862B-E9F153B9AB1BQ26823826-81106E3F-5812-46DC-8C10-DCC27A65E084Q27021839-B106331C-4436-4FBC-A69C-90C03A79BED4Q28083534-EB518598-EDB4-434F-A7C8-59FED4F43171Q33434692-D905AAF3-3372-4DB8-AED6-FC9551D0CA78Q34013572-B60E36C7-6D63-494C-8AE0-E0CF198DD131Q34325544-EE12E654-983A-45A2-8F9A-F3F0D4137F3AQ34989252-A6FD0E5B-0A9E-487A-A9D3-AC296149540CQ36664219-3FC9954F-6D1A-4255-9DF4-77DAF707167AQ36667968-D0EF9916-01CE-4562-961F-92B73C22F090Q36700481-6AA047DD-42EA-4CB9-8F99-372F295186BBQ36756897-63B1DA91-77E6-4D11-A2B7-F30DF1259504Q37031914-381459DD-4612-4120-974A-D12E39D5366FQ37104963-69A501B7-AB37-4420-B519-7122FEED80BFQ37336836-F00D2BB0-83F6-48D1-97E6-6BB0144F5E17Q37373616-DF227BA3-01F0-4886-B441-B6843BD6E6ECQ37381298-FBE3F4E6-D335-4336-8465-60B7248AEDB4Q37625385-A1406A7C-13F9-4EC7-AB14-F2647E444FD0Q38025263-D8BA5DE2-6567-493F-A170-D8A28E6A0754Q38152474-56C05D4A-F64B-4D53-8AFD-F67897DE2F01Q38734741-E1673C77-1E40-4B0B-A247-FE5D3860174BQ38780400-1A0CF849-623F-4A39-93F5-1A9D69D6140EQ38955561-2ECBB2E9-E0E5-4AE5-8B1E-21FF24059719Q39013686-3E4D6346-89FC-481A-ADB1-2E8AA4A15EB4Q39230055-AA6BE4BB-07D7-4C57-ACA7-FAADA82D4590Q39788723-B09BAC99-011E-43CA-9024-C44326AA29EDQ45324545-8A8F6D87-3180-414D-B805-544933DCADC7Q45324769-ECBC8C77-B007-41CE-8D85-F6B49A8D9DF0Q47547386-2C1E2076-7F1E-4423-8A8A-E5122FF896C5Q52674773-84E42DC1-548B-4B3F-A690-BFFC7C3F8A44Q55515625-5BFC2C08-45F9-4A85-B30F-85256323B2DAQ57016734-0323E4BB-F8BD-40D2-AD36-C9890A4A55A6
P2860
Curative one-shot systemic virotherapy in murine myeloma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Curative one-shot systemic virotherapy in murine myeloma.
@ast
Curative one-shot systemic virotherapy in murine myeloma.
@en
type
label
Curative one-shot systemic virotherapy in murine myeloma.
@ast
Curative one-shot systemic virotherapy in murine myeloma.
@en
prefLabel
Curative one-shot systemic virotherapy in murine myeloma.
@ast
Curative one-shot systemic virotherapy in murine myeloma.
@en
P2093
P2860
P356
P1433
P1476
Curative one-shot systemic virotherapy in murine myeloma.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2012.70
P577
2012-03-19T00:00:00Z